K
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is an oncology-focused biopharmaceutical company focused on the discovery, development and commercialization of novel medicines
About Karyopharm Therapeutics
Karyopharm Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines aimed at improving the lives of patients with cancer and other major diseases. The company operates in the biopharmaceutical market, focusing on both hematologic malignancies and solid tumors. Karyopharm's business model revolves around the research and development of novel drugs, with a strong emphasis on targeting nuclear export in cancer cells. This approach involves inhibiting the export of key proteins from the nucleus of cancer cells, thereby inducing cell death and reducing tumor growth. Karyopharm generates revenue through the commercialization of its proprietary drugs, partnerships, and collaborations with other research institutions and pharmaceutical companies. The company's clients primarily include healthcare providers, hospitals, and cancer treatment centers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- Newton, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A7 investors entered at this stage
Delphi Ventures
Adage Capital
Foresite Capital- HMHighbridge Capital Management
Davidson Kempner Capital Management
Braidwell
Context Capital Management
Series B and later6 investors entered at this stage
Citadel- HPHealthCor Partners
- RMRubric Capital Management
Marshall Wace
SilverArc Capital
HealthCare Royalty
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
35 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Karyopharm Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Karyopharm Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

